Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fibroblast growth factor 3 (FGF3) is a member of the FGF family, which comprises secreted signaling proteins essential for cell growth, proliferation, differentiation, and development. FGF3 is especially critical in embryonic development, where it triggers chemical signals influencing the formation and maturation of structures such as the inner and outer ears and teeth. Mutations in FGF3 are linked to congenital disorders, notably causing deafness and dental malformations (LAMM syndrome). FGF3 also possesses oncogenic potential due to its proto-oncogene classification, and aberrant expression may be implicated in certain cancers[6].
Drugs that target the FGF/FGFR pathway (such as FGFR inhibitors) typically act by blocking the receptor's kinase activity or ligand binding to inhibit downstream signaling, though these do not target FGF3 directly[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Fibroblast growth factor 3 (FGF3).